CurrentColorado Rocky Mountain Health PlansPolicy N/A

Duopa (carbidopa/levodopa) enteral suspension prior authorization

This document governs prior authorization and medical necessity criteria for Duopa enteral suspension used to treat motor fluctuations in patients with advanced Parkinson's disease for members of the payer's pharmacy program.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyDuopa (carbidopa/levodopa) enteral suspension prior authorization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateNov 1, 2025

Next Review DateN/A

Key ActionObtain documentation of advanced Parkinson’s disease and evidence that wearing 'off' is not manageable by increasing oral levodopa; confirm planned or placed procedurally placed tube for initial authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization period

16 hoursinfusion duration

Duopamedication

allowedtemporary NJ tube

Coverage Criteria for Duopa (carbidopa/levodopa) Enteral Suspension

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy

Covered when ALL of the following are met:

Initial Authorization for Duopa: (a) Diagnosis of advanced Parkinson's Disease

Initial Authorization for Duopa: (b) Patient experiences a wearing 'off' phenomenon that cannot be managed by increasing the dose of oral levodopa

Initial Authorization for Duopa: (c) Has undergone or has planned placement of a procedurally placed tube

Continuation Therapy

Covered when the following is met:

Reauthorization for Duopa: Documentation of positive clinical response to Duopa therapy

Coverage for Duopa may be affected by external requirements and member benefits. State mandates and any applicable federal regulatory requirements can alter coverage determinations. In addition, coverage is subject to the terms of the individual member’s benefit plan; member-specific benefit plan coverage may impose limits or exclusions that supersede the policy criteria. Other payer policies and utilization management programs may also apply and could affect authorizations or claim adjudication.

Provider Authorization and Documentation Requirements

Prior Authorization

Initial Authorization Requirements

Initial authorization required. Submit documentation demonstrating a diagnosis of advanced Parkinson's disease, evidence of wearing 'off' that is not manageable by increasing oral levodopa (prior optimization implied), and documentation that the patient has undergone or has a planned procedurally placed tube. Authorization, when approved, will be issued for 12 months.

Required diagnosis: advanced Parkinson's disease
Evidence of wearing 'off' symptoms not controlled by increasing oral levodopa (documents or clinician statement that oral optimization was attempted or would be insufficient)
Documentation of placement or planned placement of a procedurally placed infusion tube
Initial authorization duration: 12 months

Documentation Required

Reauthorization Requirements

Reauthorization requires documentation of ongoing benefit. Provide clinical documentation showing a positive clinical response to Duopa therapy. Reauthorizations will be issued for 12 months.

Documentation of positive clinical response (symptom improvement, reduced 'off' time, functional gains)
Reauthorization duration: 12 months

Documentation Required

Prior Optimization Implied

Prior optimization is implied and must be documented or addressed. The wearing 'off' phenomenon should be shown to be not manageable by increasing oral levodopa (or there must be clinical justification why oral optimization is not appropriate).

Record of prior attempts to optimize oral levodopa dosing OR clinician rationale why oral optimization is not appropriate or sufficient
If documentation of oral optimization attempts is missing, the request may be denied

Denial Risk

Denial Triggers for Missing Core Criteria

Requests missing core criteria are at high risk for denial. Ensure all required elements are included with the initial or reauthorization request.

Missing diagnosis of advanced Parkinson's disease
No documentation of wearing 'off' or lack of control with increased oral levodopa
No documentation of planned or placed infusion tube
No evidence of positive clinical response for reauthorization requests

Key Definitions

Duopa (carbidopa/levodopa) — definition and administration

Generic nameCarbidopa/levodopa enteral suspension

Brand nameDuopa

Indication (policy)Treatment of motor fluctuations in advanced Parkinson's disease

Route and administrationContinuous enteral infusion via an infusion pump through a procedurally-placed tube (approximately 16 hours daily); naso-jejunal (NJ) tube allowed short-term until gastrostomy placement

Typical daily infusion durationApproximately 16 hours per day

Wearing 'off' phenomenon — definition and policy-specific interpretation

Policy interpretationFor Duopa eligibility, wearing 'off' must be present and not manageable by increasing the dose of oral levodopa — implying prior optimization of oral levodopa dosing

Clinical implicationWear 'off' that is controllable by oral levodopa dose escalation does not meet this policy's criteria for Duopa

Background on Duopa and Clinical Context

Duopa is a carbidopa/levodopa enteral suspension indicated for treatment of motor fluctuations in patients with advanced Parkinson’s disease. It is administered as a continuous infusion via an infusion pump for approximately 16 hours daily through a procedurally placed enteral tube; a naso-jejunal (NJ) tube may be used short-term until gastrostomy placement. The therapy is intended for patients with disabling motor fluctuations — specifically a wearing “off” phenomenon that is not manageable by increasing oral levodopa dosing.